Overview

BioMedical Technology Solutions Holdings, Inc., located in Englewood, Colorado, sells the Demolizer® II through its wholly owned subsidiary BioMedical Technology Solutions, Inc. BMTS' patented Demolizer® Technology converts infectious biomedical waste into non-infectious material. BMTS' products provide biomedical waste treatment solutions for the over 1,000,000 low to medium volume medical waste generators in the US and a global market five times larger than the US.

---

Investment Highlights

---

Profile

With a constant shift in the world’s trend to protect our planet, biomedical waste is regularly in the news due to its dangerous nature to harm both people and the environment if it is not properly collected and destroyed. The biomedical waste industry is one that slips past many investors as, quite simply, it is generally looked at as garbage disposal. Taking that for what it is, it is important to realize that it is a multi-billion dollar industry and as regular and dependable from an investment standpoint as any other industry in the world. Face it, people are always going to need medical attention and that generates waste, which is federally regulated and mandates proper disposal. It is unavoidable.

In the United States alone, biomedical waste is on the rise. In 2008, over five pounds of medical waste was generated for each person in the United States. This equates to 1.5 billion pounds that must be accounted for and properly disposed according to government regulations. Twenty years ago, the industry was only valued at approximately $750 million. Growing at approximately a 25% rate, the industry surged through $1 billion in 1995 and is conservatively estimated that it will reach $3.2 billion annually by the year 2015.

Our aging population, which requires more care, coupled with several other factors, including a concerted effort to ensure that the hazardous waste does not damage a person or our environment are driving forces in the industry’s growth. The federal government requires "cradle-to-grave" tracking of medical waste, including sharps. In simple terms, this means that a log must be kept from the moment that biohazardous waste is generated until the time it reaches its final destination at a waste facility and is properly destroyed. Many states also require that a “destruction certificate” is also issued documenting the log and destruction of the biomedical waste.

Given the gravity of the waste and the contamination component of it, haulers (companies that pick-up the waste from a facility and take it to a different location for destruction) charge exorbitant amounts of money to provide the service. Stericycle, Inc., the monster of the industry with a $7 billion dollar market cap, has proven just how profitable the industry can be. Waste Management, Inc., a global leader in garbage removal, has recently thrown its hat into the biomedical waste disposal ring in an effort to penetrate the industry that is resistant to recessions and volatility.

The fact is that biomedical waste is generated everywhere you look. Hospitals, medical centers, dentists, sports facilities, veterinary clinics, assisted living facilities, airports, equine facilities, pharmacies that provide flu shots, etc. If a needle is used or blood flows, it’s a biohazard and must be disposed of as such. The diabetic community alone generates over 1 billion used needles annually.

Small to medium volume generators of waste are the main targets for potential clients due to sheer numbers and profit margins. Whereas there are only approximately 17,000 hospitals in the U.S. (considered large volume generators), there are over one million small to medium volume generators of waste. To demonstrate the value of these smaller customers, in 1996, approximately 75% of Stericycle’s business was generated from large volume generators. In 2006, the roles had reversed, as now 75% of their business is derived through small to medium volume generators.

Most importantly, these smaller volume generators have been subject to the effects of the recession just like the rest of the world. As a result, cost cutting measures are being exercised at a pace never seen before. Patient loads are still strong and must be maintained or even increased while efficiencies are maximized in order to keep operating margins as highs as possible. With a typical, four-doctor general practice averaging hauling costs of biomedical waste in excess of $4,000 per year; it is certainly a source of topic for cost reduction measures.

Englewood, Colorado-based BioMedical Technology Solutions Holdings, Inc. (OTCBB:BMTL) operates through its wholly-owned subsidiary, BioMedical Technology Solutions, Inc. (“BMTS”) and is emerging as an industry leader in biomedical waste management because it provides a solution that encompasses all the issues with biomedical waste in one product. The Company manufactures and markets the Demolizer® II, the world’s only portable and patented machine that processes both sharps and typical “red bag” waste onsite so it can be disposed of as common trash. The Demolizer II addresses the issues of expensive hauling services, eliminates “cradle-to-grave” liabilities, and is the only “green” product of its kind; addressing environmental concerns.

The Demolizer® II is a unit approximately the size of a desktop copier that plugs into a standard wall outlet and, with the push of two buttons, processes sharps and infectious red bag waste so it is rendered 100% sterile and able to be disposed of with any other regular trash generated by the facility. In reality, once processed, it is the most sterile item in the trash. In addition, the machine prints all necessary documentation to maintain strict compliance with all government mandates; eliminating all “cradle-to-grave” responsibilities. The fact that it brings all of these features to its users and comes at a cost that offers a significant reduction to hauling services is leading to rising popularity and sales. This was reflected in BMTL’s last quarterly report which showed revenues were up by 107% as compared to the year prior’s quarter. In addition to this astounding revenue growth, the BMTS management slashed expenses by 38% at the same time.

We have written in the past about how valuable government contracts can be for any company. BioMedical Technology Solutions has proven its value to the government through contracts over the years with Demolizer® II units currently being used by the U.S. Air Force and U.S. Department of Veteran Affairs. Industry leaders, US HealthWorks and Hospital Corporation of America are also corporations that are realizing the benefits of the Demolizer® II and have placed repeat orders. Even Coors Field, home of a professional baseball team has one on site.

Echoing the value of the Demolizer® II units, Joseph Mallas, Executive Vice President of Operation for U.S. HealthWorks, had this to say after the three-month program was completed: "Usage of the Demolizer® II has helped us lower the cost of biomedical waste management by 70%, exceeding our initial projected savings. We are looking forward to rolling this out to more of our centers nationwide." Since that statement, another round of units has been ordered and received by the owner of medical facilities nationwide.

While the potential for Demolizer® II contracts within the United States provides a billion-dollar possibility, BioMedical Technology Solutions holds patents throughout the world and has distribution agreements in place globally. A recent patent was issued in Russia as biomedical waste disposal there and throughout Europe is growing exponentially and is a major topic of health concerns and legislative discussions. With the Demolizer® II technology protected throughout the world, BMTS is there to provide the solution as more strict enforcement of proper biomedical waste management is starting to happen.

BMTS leverages the expansiveness and recognition of its distribution partner Henry Schein Medical, one of the largest medical device distributors in the United States to perpetuate repeat sales and generate new customers. Additionally, a new distribution agreement was signed with GroupSource to end 2010 with a bang. With an extensive reach to more than 130,000 physicians, GroupSource is focused on group purchasing to negotiate contracts to reduce hard dollar costs. The partnerships with Henry Schein, PSS, Patterson Dental and this new agreement with GroupSource in combination with recurring orders through additional customers has BioMedical Technology Solutions well-positioned to expand its footprint within the industry to a great extent in this New Year.

With only 32 million shares issued and outstanding and a tiny float of around 7 million, BMTL also has a serious competitive edge on its larger competitors as overall profits increase bottom line numbers drastically with every unit sold. The Company is run at an efficient level that produces a 50 to 60 percent gross margin presently with continued efforts ongoing to cut overhead even more in the interest of the Company and its shareholders.

Technically speaking, the BMTL chart may be poised for a rise. The price per share had one brief touch of a 52-week low at 10 cents which resulted in a quick climb on that day to over 12 cents. Technical traders will look for separation of key indicators which can often mean a technical reversal is in the making and that appears to be happening even though the value of a share has still not touched that same bottom level.

The commonly used Moving Average Convergence Divergence (MACD) appears as if it could be turning to make a higher low. This is the most common sign of positive divergence that technical traders are in search of for a stock ready to make a climb as the separation is wide from the signal line, yet looks to be at the early stages of flattening. Volume based indicators such as the Money Flow Index (MFI) are a tell-tale sign as to the true volume of buying versus selling in a stock and that shows that the buying pressure today was much heavier than the selling pressure. The much-used Full Stochastics is at levels that produced a bounce from $0.19 to $0.24 the last time in February.

Moreover, the Relative Strength Index, which follows momentum of a stock is still seeing its long-term components still in the area of 50 which indicates indecision in momentum. Much like so many other stocks that we have looked at recently, BMTL appears to be held down technically by very low volume selling which our experience tells us is not substantial to the true value of the share price. Strong resistance does not enter the picture until the area of 23 cents, representing a more than 100 percent gain from today’s closing price, which will have technical traders looking very closely at this undervalued play. With the 52 week low being at $0.10 a share, that will continue to be a strong support level and stop losses just below that price would be encouraged to protect against any possible further drops in price. As always, the above interpretations are merely AllPennyStocks.com's interpretations of the BMTL stock chart, and investors are strongly encouraged to do their own due diligence and consult with a financial advisor prior to making any trades.

Even though the technical aspects of the BMTL stock chart show promise, investors will be more excited by the Company's recent fundamentals. The Company announced after the bell on May 16th, 2011 their latest 10Q filings. According to the 10Q, revenues were $183,340 in 2011, up from $162,704 in 2010. The increase (13%) was due to changes in management, refocused efforts in product marketing and supporting distributors. The Company's cost of revenue for 2011 also rose and was pegged at $101,915 up from $75,813 from the prior year. The increase (34%) is attributed to increased revenue. The Company's cost of sales as a percentage of revenue decreased to 45% of revenue for the quarter ended March 31, 2011 down from 53% for 2010 due to product revenue mix. Lastly, for the quarter ended March 31, 2011, the Company incurred a net loss of $81,196, compared to a net loss of $413,434 for 2010, a decrease in net loss of $332,238 or 80%. The decrease in net loss was due to a change in management and implementation of major cost cutting measures. This Company is definitely shaping up quite well from a fundamental perspective, and with more eyeballs watching BMTL, it may translate to plenty of more liquidity for this quiet but very impressive Company.

It is no secret that the world continues to migrate towards green technologies and every company out there is looking for a way to save money each month. Throw in the mix that biomedical waste disposal is not only not going away; it is increasing regularly in cost and visibility for proper disposal. There is no other technology on the market that does what the Demolizer® II does and as BioMedical Technology Solutions continues to gather momentum through large-scale distribution agreements and penetration of the global market, this Company will not be flying under the radar of the investment community for long. It is for this reason, as well as those mentioned above, that we at AllPennyStocks have decided to turn our spotlight on BioMedical Technology Solutions Holdings, Inc. (OTCBB:BMTL) and encourage our members to perform their due diligence on the Company and add it to their watchlists.

---

Recent News and Press Releases

BIOMEDICAL TECHNOLOGY SOLUTIONS HOLDINGS INC Files SEC form 10-Q, Quarterly Report
EDGAR Online (Mon, May 16)

 

BioMedical Technology Solutions Receives Signed Letter of Intent Valued in Excess of $2 Million From New International Distributor Marketwire (Tue, Jan 11)

 

BMTL Expands Reach to the Physician Market Through a New Distribution Agreement With GroupSource Marketwire (Wed, Dec 15)

BioMedical Technology Solutions Strengthens International Position With New Russian Patent for Demolizer(R) II Technologies Marketwire (Tue, Nov 16)

BioMedical Technology Solutions, Inc. and Distribution Partner, Henry Schein, Continue Nationwide Roll-Out of Demolizer(R) II in US HealthWorks Locations Marketwire (Tue, Oct 5)
 

---

Management

Jonathan Bricken - CEO

Gex Richardson, Esq. - President, Chairman of the Board and Secretary

Gex Richardson, ESQ, serves as in-house counsel and is a senior investor in BioMedical Technology Solutions, Inc. Mr. Richardson is also the Senior Vice President /General Counsel of Glenn Wright Construction & Development, Inc. which is a $200 Million Dollar a year Real Estate Development Company in Fort Lauderdale, Florida. Previously, Mr. Richardson was Of Counsel to Akerrman Senterfitt, one of the largest law firms in Florida, specializing in corporate transaction and real estate. Mr. Richardson has been practicing law for 17 years since graduating from the University of Florida with a BSBA in finance and a Juris Doctor.

Tom Von Bank - National Director of Sales

Tom Von Bank, National Director of Sales, oversees all revenue generating initiatives for the Company. He has extensive experience with building and managing sales teams, working with distributors, and applying a scalable process to growing profitable revenue. Tom comes to BMTS with over 23 years' experience in medical sales, sales management and sales distribution from a variety of medical organizations ranging from Fortune 50 companies to pre-IPO top 100 Dunn and Bradstreet start-up organizations, including BioMet, VitaMed, US Medical and Lexicor Medical Technology. Tom had designed nationally recognized sales and marketing programs. Mr. Von Bank brings significant medical and sales experiences to BMTS to support the full scale launch of the Demolizer® and related technologies.

Chuck Chapman - Regional Sales Director

---

Contact

BioMedical Technology Solutions, Inc.
9800 Mount Pyramid Court, Suite 250
Englewood, Colorado 80112

Phone:
Toll Free:
866.525.BMTS (2687)

In the Denver, Colorado Metro Area :
303.653.0100

Fax:
303.653.0120

---

FORWARD LOOKING STATEMENTS

This report includes forward-looking statements that reflect BioMedical Technology Solutions Holdings, Inc. current expectations about its future results, performance, prospects and opportunities. BioMedical Technology Solutions Holdings, Inc. has tried to identify these forward-looking statements by using words and phrases such as "may," "will," "expects," "anticipates," "believes," "intends," "estimates," "plan," "should," "typical," "preliminary," "we are confident" or similar expressions. These forward-looking statements are based on information currently available and are subject to a number of risks, uncertainties and other factors that could cause BioMedical Technology Solutions Holdings, Inc.'s actual results, performance, prospects or opportunities to differ materially from those expressed in, or implied by, these forward-looking statements. These risks, uncertainties and other factors include, without limitation, the Company's growth expectations and ongoing funding requirements, and specifically, the Company's growth prospects with scalable customers, and those outlined above. Other risks include the Company's limited operating history, the Company's history of operating losses, consumers' acceptance, the Company's use of licensed technologies, risk of increased competition, the potential need for additional financing, the terms and conditions of any financing that is consummated, the limited trading market for the Company's securities, the possible volatility of the Company's stock price, the concentration of ownership, and the potential fluctuation in the Company's operating results.

---

Disclaimer

AllPennyStocks.com feature stock reports are intended to be stock ideas, NOT recommendations. Please do your own research before investing. It is crucial that you at least look at current SEC filings and read the latest press releases. Information contained in this report was extracted from current documents filed with the SEC, the company web site and other publicly available sources deemed reliable. For more information see our disclaimer section, a link of which can be found on our web site. This document contains forward-looking statements, particularly as related to the business plans of the Company, within the meaning of Section 27A of the Securities Act of 1933 and Sections 21E of the Securities Exchange Act of 1934, and are subject to the safe harbor created by these sections. Actual results may differ materially from the Company's expectations and estimates. This is an advertisement for BioMedical Technology Solutions Holdings, Inc. The purpose of this advertisement, like any advertising, is to provide coverage and awareness for the company. The information provided in this advertisement is not intended for distribution to, or use by, any person or entity in any jurisdiction or country where such distribution or use would be contrary to law or regulation or which would subject us to any registration requirement within such jurisdiction or country.

© 1999-2011 AllPennyStocks.com. All rights reserved. AllPennyStocks.com is not a Registered Broker/Dealer or Financial Advisor, nor do we hold ourselves out to be. All materials presented on our web site and individual reports released to the public through this web site, e-mail or any other means of transmission are not to be regarded as investment advice and are only for informative purposes. Before making a purchase or sale of any securities featured on our web site or mentioned in our reports, we strongly encourage and recommend consultation with a registered securities representative. This is not to be construed as a solicitation or recommendation to buy or sell securities. As with any stock, companies we select to profile involve a degree of investment risk and volatility. Particularly Small-Caps and OTC-BB stocks. All investors are cautioned that they may lose all or a portion of their investment if they decide to make a purchase in any of our profiled companies. Past performance of our profiled stocks is not indicative of future results. The accuracy or completeness of the information on our web site or within our reports is only as reliable as the sources they were obtained from. The profile and opinions expressed herein are expressed as of the date the profile is posted on site and are subject to change without notice. No investor should assume that reliance on the views, opinions or recommendations contained herein will produce profitable results. AllPennyStocks.com may hold positions in securities mentioned herein, and may make purchases or sales in such securities featured on our web site or within our reports. In order to be in full compliance with the Securities Act of 1933, Section 17(b), AllPennyStocks.com will disclose in it's disclaimer, what, if any compensation was received for our efforts in researching, presenting and disseminating this information to our subscriber database and featuring the report on the AllPennyStocks.com web site. AllPennyStocks.com has been compensated fourteen thousand five hundred dollars in October 2009 and one hundred thousand rule-144 restricted shares of BMTL on January 2011 from the Company for its efforts in presenting the BMTL profile on its web site and distributing it to its database of subscribers as well as other services. AllPennyStocks.com may decide to purchase or sell shares on a voluntary basis in the open market before, during or after the profiling period of this report. As of the profile date, no shares have been sold. Information presented on our web site and within our reports contain "forward looking statements" within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. Any statements that express or involve discussions with respect to predictions, expectations, beliefs, plans, projections, objectives, goals, assumptions or future events or performance are not statements of historical fact and may be "forward looking statements." Forward looking statements are based on expectations, estimates and projections at the time the statements are made that involve a number of risks and uncertainties which could cause actual results or events to differ materially from those presently anticipated. Forward looking statements in this action may be identified through the use of words such as “expects’”, “will,” “anticipates,” “estimates, “believes,” or that by statements indicating certain actions “may,” “could,” or “might” occur.

THE READER SHOULD VERIFY ALL CLAIMS AND DO THEIR OWN DUE DILIGENCE BEFORE INVESTING IN ANY SECURITIES MENTIONED. INVESTING IN SMALL CAP SECURITIES IS SPECULATIVE AND CARRIES A HIGH DEGREE OF RISK.

We encourage our readers to invest carefully and read the investor information available at the web sites of the Securities and Exchange Commission (SEC) at: http://www.sec.gov and/or the National Association of Securities Dealers (NASD) at: http://www.nasd.com. Readers can review all public filings by companies at the SEC's EDGAR page. The NASD has published information on how to invest carefully at its web site.